BCMA / TACI

Class

Autologous CAR-T cell therapy — engineered via non-viral transposon system to express a CAR built from the natural ligand BAFF (B-cell activating factor) rather than an scFv, so it engages any BAFF-receptor-family member expressed on the tumor cell (BCMA and TACI)

Notes

original target text: BCMA / TACI (via BAFF ligand-based CAR binder, targeting BAFF-receptor family members)

BCMA and TACI are two related receptor proteins that sit on the surface of plasma cells, the antibody-producing cells of the immune system, and are especially abundant on the malignant plasma cells found in multiple myeloma. Both receptors normally receive survival signals from soluble proteins called BAFF and APRIL, which support the growth and persistence of plasma cells. Because these receptors are so selectively concentrated on plasma cells, they are attractive handles for engineered immune therapies designed to seek out and destroy myeloma cells. This particular approach uses a chimeric antigen receptor (CAR) T-cell therapy: a patient's own T cells are re-engineered, using a non-viral transposon delivery method, to display a CAR whose recognition domain is built from BAFF itself rather than an antibody fragment. Since BAFF is the natural ligand for both BCMA and TACI, the resulting CAR-T cells can recognize either receptor on a tumor cell, rather than being restricted to just one. This dual engagement is intended to broaden tumor coverage and reduce the chance that cancer cells evade treatment by losing a single target receptor. The mechanism sits within the broader field of adoptive cellular immunotherapy for hematologic malignancies, particularly relapsed or treatment-resistant plasma cell disorders.